Moderna, Inc. Furnishes Financial Results and Business Updates
Summary
On November 6, 2025, Moderna, Inc. furnished its financial results for the third quarter ended September 30, 2025, via Exhibit 99.1 press release. The company reported third quarter revenue of $1.0 billion, a GAAP net loss of $(0.2) billion, and GAAP EPS of $(0.51). * Narrows 2025 projected revenue range to $1.6 - $2.0 billion. * Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion. * Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion.
Why It Matters
The report provides key financial metrics for Q3 2025, including revenue, net loss, and EPS, along with updated 2025 guidance for revenue, operating expenses, and cash balance. These updates, particularly the narrowed revenue range and improved operating expense outlook, are crucial for investor valuation and future projections.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Thursday, November 6, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral